Boehringer, Teva Sued Over $120M Pay-For-Delay Deal

Law360, New York (January 3, 2014, 7:10 PM EST) -- Drug distributor American Sales Co. on Thursday hit Boehringer Ingelheim Pharmaceuticals Inc. and Teva Pharmaceuticals USA Inc. with a proposed class action over an alleged $120 million pay-for-delay deal, the latest in a spate of suits over agreements to keep generic medicines off the market.

American Sales, which says it paid more than it should have for stroke medicine Aggrenox, is at least the second company to sue Boehringer and Teva over the reverse-payment arrangement, joining wholesaler Miami-Luken Inc., which filed suit in November. 

According to...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.